210 related articles for article (PubMed ID: 37550187)
41. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
42. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
43. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
44. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
45. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
46. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.
Tees MT; Flinn IW
Expert Rev Hematol; 2017 Feb; 10(2):137-146. PubMed ID: 27936980
[TBL] [Abstract][Full Text] [Related]
47. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Markers in the Era of Targeted Therapies.
Kang S; Ahn IE
Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
[TBL] [Abstract][Full Text] [Related]
49. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
50. Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Viswanathan K; Roboz G; Chadburn A; Mathew S
Int J Surg Pathol; 2020 Apr; 28(2):216-224. PubMed ID: 31544558
[TBL] [Abstract][Full Text] [Related]
51. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
52. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
[TBL] [Abstract][Full Text] [Related]
53. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
54. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
[TBL] [Abstract][Full Text] [Related]
55. BTK Inhibitor Options Expand for CLL/SLL.
Cancer Discov; 2023 Feb; 13(2):252. PubMed ID: 36524825
[TBL] [Abstract][Full Text] [Related]
56. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Shanafelt TD; Kay NE; Rabe KG; Inwards DJ; Zent CS; Leis JF; Schwager SM; Thompson CA; Bowen DA; Witzig TE; Slager SL; Call TG
Cancer; 2012 Apr; 118(7):1827-37. PubMed ID: 22009554
[TBL] [Abstract][Full Text] [Related]
57. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
58. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Tsimberidou AM; Wen S; O'Brien S; McLaughlin P; Wierda WG; Ferrajoli A; Faderl S; Manning J; Lerner S; Mai CV; Rodriguez AM; Hess M; Do KA; Freireich EJ; Kantarjian HM; Medeiros LJ; Keating MJ
J Clin Oncol; 2007 Oct; 25(29):4648-56. PubMed ID: 17925562
[TBL] [Abstract][Full Text] [Related]
59. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
[TBL] [Abstract][Full Text] [Related]
60. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
